Takayuki Shiroyama

3.7k total citations
112 papers, 1.4k citations indexed

About

Takayuki Shiroyama is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Takayuki Shiroyama has authored 112 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Pulmonary and Respiratory Medicine, 61 papers in Oncology and 18 papers in Surgery. Recurrent topics in Takayuki Shiroyama's work include Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Diagnosis and Treatment (30 papers) and Lung Cancer Research Studies (29 papers). Takayuki Shiroyama is often cited by papers focused on Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Diagnosis and Treatment (30 papers) and Lung Cancer Research Studies (29 papers). Takayuki Shiroyama collaborates with scholars based in Japan, United States and United Kingdom. Takayuki Shiroyama's co-authors include Tomonori Hirashima, Motohiro Tamiya, Norio Okamoto, Hidekazu Suzuki, Shinji Atagi, Akihiro Tamiya, Fumio Imamura, Naoko Morishita, Yoshihiko Taniguchi and Kenji Nakahama and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Takayuki Shiroyama

101 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takayuki Shiroyama Japan 19 858 826 137 137 133 112 1.4k
V. Gounant France 23 831 1.0× 960 1.2× 123 0.9× 167 1.2× 267 2.0× 133 1.6k
Wolfgang Gesierich Germany 14 532 0.6× 824 1.0× 196 1.4× 184 1.3× 199 1.5× 63 1.4k
Takanori Ayabe Japan 17 754 0.9× 461 0.6× 156 1.1× 158 1.2× 146 1.1× 103 1.2k
Akimasa Sekine Japan 18 303 0.4× 862 1.0× 98 0.7× 267 1.9× 83 0.6× 130 1.1k
Shinjiro Sakamoto Japan 16 331 0.4× 428 0.5× 66 0.5× 89 0.6× 135 1.0× 98 838
Funda Demirağ Türkiye 19 259 0.3× 799 1.0× 320 2.3× 108 0.8× 138 1.0× 119 1.2k
Wan‐Lun Hsu Taiwan 20 555 0.6× 175 0.2× 319 2.3× 141 1.0× 147 1.1× 59 1.1k
Savina Aversa Italy 18 426 0.5× 256 0.3× 94 0.7× 223 1.6× 83 0.6× 44 947
Yeona Cho South Korea 16 359 0.4× 295 0.4× 173 1.3× 58 0.4× 45 0.3× 58 855
Kakuhiro Yamaguchi Japan 15 222 0.3× 470 0.6× 49 0.4× 84 0.6× 96 0.7× 93 751

Countries citing papers authored by Takayuki Shiroyama

Since Specialization
Citations

This map shows the geographic impact of Takayuki Shiroyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takayuki Shiroyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takayuki Shiroyama more than expected).

Fields of papers citing papers by Takayuki Shiroyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takayuki Shiroyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takayuki Shiroyama. The network helps show where Takayuki Shiroyama may publish in the future.

Co-authorship network of co-authors of Takayuki Shiroyama

This figure shows the co-authorship network connecting the top 25 collaborators of Takayuki Shiroyama. A scholar is included among the top collaborators of Takayuki Shiroyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takayuki Shiroyama. Takayuki Shiroyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Matsumoto, Kinnosuke, Akihiro Tamiya, Motohiro Tamiya, et al.. (2025). Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study. European Journal of Cancer. 228. 115748–115748.
3.
Miyake, Kotaro, Masahide Oki, Hidekazu Suzuki, et al.. (2025). Balloon Dilatation for Bronchoscope Delivery: First-in-Human Trial of a Novel Technique for Ultra-peripheral Lung Field Access. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A2731–A2731.
4.
Miyamoto, Shimpei, Hanako Kuhara, Takayuki Shiroyama, et al.. (2025). Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. 16(6). e70047–e70047. 1 indexed citations
5.
6.
Shintani, Takuya, Kenji Ikemura, Takayuki Shiroyama, et al.. (2024). MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma. Scientific Reports. 14(1). 24429–24429.
7.
Satoh, S., Kotaro Miyake, Yuichi Adachi, et al.. (2024). Cancer-associated SNRPD3 mutation confers resistance to hypoxia, which is attenuated by DRP1 inhibition. Biochemical and Biophysical Research Communications. 696. 149511–149511. 1 indexed citations
8.
Nishio, Makoto, Shuji Murakami, Hisato Kawakami, et al.. (2024). Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Research Communications. 4(1). 226–235. 2 indexed citations
9.
Abe, Yuko, Kotaro Miyake, Takayuki Shiroyama, et al.. (2023). Virtual fluoroscopic preprocedural planning using Ziostation2 for transbronchial biopsy: A prospective self-controlled study. Respiratory Investigation. 61(2). 157–163. 1 indexed citations
10.
Matsumoto, Kinnosuke, Takayuki Shiroyama, Kotaro Miyake, et al.. (2022). Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma. Medicine. 101(1). e28476–e28476. 4 indexed citations
11.
Suzuki, Hidekazu, Takayuki Shiroyama, Ayako Tanaka, et al.. (2020). Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study. Investigational New Drugs. 38(6). 1915–1920. 8 indexed citations
12.
Kimura, Masashi, Kazumi Nishino, Yukihiro Yano, et al.. (2019). P2.16-19 Real World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation - A Multicenter Observational Study. Journal of Thoracic Oncology. 14(10). S872–S873.
13.
Osa, Akio, Takeshi Uenami, Yujiro Naito, et al.. (2019). Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis. Thoracic Cancer. 10(11). 2183–2187. 10 indexed citations
14.
Shiroyama, Takayuki, Hidekazu Suzuki, Motohiro Tamiya, et al.. (2018). Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Research. 38(8). 4723–4729. 43 indexed citations
15.
Masuhiro, Kentaro, Takayuki Shiroyama, Hidekazu Suzuki, et al.. (2018). Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC HarboringEGFRT790M. Anticancer Research. 38(6). 3567–3571. 11 indexed citations
16.
Tamiya, Motohiro, Akihiro Tamiya, Takayuki Shiroyama, et al.. (2017). Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. Investigational New Drugs. 36(4). 608–614. 3 indexed citations
17.
18.
Hirashima, Tomonori, Hidekazu Suzuki, Norio Okamoto, et al.. (2014). Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncology Letters. 8(1). 327–334. 6 indexed citations
19.
Tamiya, Akihiro, Motohiro Tamiya, Takayuki Shiroyama, et al.. (2012). Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Annals of Oncology. 24(4). 980–985. 22 indexed citations
20.
Shiroyama, Takayuki, Takashi Kijima, Kiyoshi Komuta, et al.. (2012). Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 30(15_suppl). e18141–e18141. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Gounant Breakdown of academic impact, for papers by Wolfgang Gesierich Breakdown of academic impact, for papers by Takanori Ayabe Breakdown of academic impact, for papers by Akimasa Sekine Breakdown of academic impact, for papers by Shinjiro Sakamoto Breakdown of academic impact, for papers by Funda Demirağ Breakdown of academic impact, for papers by Wan‐Lun Hsu Breakdown of academic impact, for papers by Savina Aversa Breakdown of academic impact, for papers by Yeona Cho Breakdown of academic impact, for papers by Kakuhiro Yamaguchi
Rankless by CCL
2026